» Articles » PMID: 26673827

Quantification of the Concentration Gradient of Biomarkers Between Ovarian Carcinoma Interstitial Fluid and Blood

Overview
Journal BBA Clin
Publisher Elsevier
Specialty Biochemistry
Date 2015 Dec 18
PMID 26673827
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Tumor interstitial fluid (TIF) rather than plasma should be used in cancer biomarker discovery because of the anticipated higher concentration of locally produced proteins in the tumor microenvironment. Nevertheless, the actual TIF-to-plasma gradient of tumor specific proteins has not been quantified. We present the proof-of-concept for the quantification of the postulated gradient between TIF and plasma.

Methods: TIF was collected by centrifugation from serous (n = 19), endometrioid (n = 9) and clear cell (n = 3) ovarian carcinomas with early (n = 15) and late stage (n = 16) disease in grades 1 (n = 2), 2 (n = 8) and 3 (n = 17), and ELISA was used for the determination of CA-125, osteopontin and VEGF-A.

Results: All three markers were significantly up-regulated in TIF compared with plasma (p < 0.0001). The TIF-to-plasma ratio of the ovarian cancer biomarker CA-125 ranged from 1.4 to 24,300 (median = 194) and was inversely correlated to stage (p = 0.0006). The cancer related osteopontin and VEGF-A had TIF-to-plasma ratios ranging from 1 to 62 (median = 15) and 2 to 1040 (median = 59), respectively. The ratios were not affected by tumor stage, indicative of more widespread protein expression.

Conclusion: We present absolute quantitative data on the TIF-to-plasma gradient of selected proteins in the tumor microenvironment, and demonstrate a substantial and stage dependent gradient for CA-125 between TIF and plasma, suggesting a relation between total tumor burden and tissue-to-plasma gradient.

General Significance: We present novel quantitative data on biomarker concentration in the tumor microenvironment, and a new strategy for biomarker selection, applicable in future biomarker studies.

Citing Articles

Role of the afferent lymph as an immunological conduit to analyze tissue antigenic and inflammatory load.

Nanaware P, Khan Z, Clement C, Shetty M, Mota I, Seltzer E Cell Rep. 2024; 43(6):114311.

PMID: 38848214 PMC: 11233987. DOI: 10.1016/j.celrep.2024.114311.


Biomarkers for immunotherapy for treatment of glioblastoma.

Lynes J, Nwankwo A, Sur H, Sanchez V, Sarpong K, Ariyo O J Immunother Cancer. 2020; 8(1).

PMID: 32474411 PMC: 7264836. DOI: 10.1136/jitc-2019-000348.


Multiplexed Remote SPR Detection of Biological Interactions through Optical Fiber Bundles.

Desmet C, Vindas K, Meza R, Garrigue P, Voci S, Sojic N Sensors (Basel). 2020; 20(2).

PMID: 31963277 PMC: 7014493. DOI: 10.3390/s20020511.


Paracrine signalling of AGR2 stimulates RhoA function in fibroblasts and modulates cell elongation and migration.

Mangukiya H, Negi H, Merugu S, Sehar Q, Saidi Mashausi D, Yunus F Cell Adh Migr. 2019; 13(1):332-344.

PMID: 31710263 PMC: 6844563. DOI: 10.1080/19336918.2019.1685928.


Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization.

Guo H, Zhu Q, Yu X, Merugu S, Mangukiya H, Smith N Oncogene. 2017; 36(36):5098-5109.

PMID: 28481872 DOI: 10.1038/onc.2017.132.


References
1.
Cao D, Li Z, Jiang X, Lum Y, Khin E, Lee N . Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers. World J Gastroenterol. 2012; 18(30):3923-30. PMC: 3419986. DOI: 10.3748/wjg.v18.i30.3923. View

2.
Liotta L, Ferrari M, Petricoin E . Clinical proteomics: written in blood. Nature. 2003; 425(6961):905. DOI: 10.1038/425905a. View

3.
Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A . Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10(4):327-40. DOI: 10.1016/S1470-2045(09)70026-9. View

4.
Bast Jr R . CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer. 2010; 116(12):2850-3. PMC: 2988470. DOI: 10.1002/cncr.25203. View

5.
Sun M, Shariat S, Cheng C, Ficarra V, Murai M, Oudard S . Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. Eur Urol. 2011; 60(4):644-61. DOI: 10.1016/j.eururo.2011.06.041. View